A Clinical Evaluation of Management of Amavata with Rasonadi kwatha, w.s.r. to Rheumatoid Arthritis

Neelakanta Sajjanar, Debajit Bhattacharyya, Shobha Itnal


Purpose: To evaluate the role of Rasonadi kwatha, a classical medicament in the management of Amavata, w.s.r. to Rheumatoid Arthrits, which is attributed with best Amavatahara property, considering a trend of progressively increasing incidence of the condition.

Methods: The trial drug Rasonadi kwatha was prepared as per the classical method of Kashaya kalpana. Total of 47 patients of Amavata fulfilling the inclusion criteria were registered, of which 30 completed the course of intervention, in a single armed, prospective, open label, cohort study, with pre and postintervention analysis design. Descriptive data including Mean, Standard Deviation (SD), Standard Error (SE), t-value and percentages were calculated for all variables in the trial group. The post treatment changes were assessed by paired Student t-test, taking 0.05 as the level of significance.

Results: Effect of the intervention on Subjective criteria including Signs and symptoms of Amavata and objective criteria including Disease Activity Score 28, Grip strength, Foot Pressure and Range of Movement was statistically significant with P value 0.001 after completion of treatment. The trial drug showed 36.67% of Moderate improvement and 53.33% of mild improvement in subjects of Amavata in the present study.

Conclusion: The formulation Rasonadi kwatha is efficacious in management of the disease Amavata w.s.r. to Rheumatoid Arthritis. The formulation is Ruksha (Dry) and Ushna (Hot potency) and thus it is a potent Amapachaka (digesting the Ama), breaking the primary pathogenesis of the disease. It showed statistically significant improvements in Samanya lakshanas and good results in Pradhana lakshanas of Amavata.


Amavata, Disease Activity Score 28, Rheumatoid Arthritis, Rasonadi kwatha

Full Text:



Colledge NR, Walkar BR, Ralstan HS. Davidson’s

principle sand practice of medicine. 20thed., Churchill

Livingstone, Toronto. 2006: 1101-1106.

Edwards CRW, Haslett C, Chilvers E et al. Davidson’s

principles and practice of medicine. 17th ed., Churchill

Livingstone, Edinburgh. 1995: 838.

Sen G. Bhaisajya Ratnavali. 18thed. Chaukhamba

Prakashan, Varanasi. 2007: 615.

Arnett FC, Edworthy SM, Bloch DA et al. The American

Association 1987 revised criteria for the classification

of rheumatoid arthritis. Arthritis Rheumatism 1988;

: 315-24.

Prevoo MLL, Van ‘T Hoff MA. Modified disease activity

scores that include twenty-eight-joint counts. Arthritis

Rheumatism 1995; 38: 44-8.

Greenwood MC, Hakimn AJ, Doyle DV. A simple

extension to the Rheumatoid Arthritis Quality of Life

Questionnaire (RAQol) to explore individual patient

concerns and monitor group outcome in clinical

practice. Rheumatology 2006; 45(1): 61-5.

Sharngdhara. Sharngdhara samhita.Varanasi:

Chaukhamba surabharati prakashan; 2006: 144.

Therapy of rheumatoid arthritis: new developments

and trends. St Clair EW, Curr Rheumatol Rep 1999

Dec; 1(2): 149-56

Smolen JS, Landewe R, Bijlsma J et al. EULAR

recommendations for the management of rheumatoid

arthritis with synthetic and biological disease-modifying

antirheumatic drugs: 2016 update. Ann Rheum Dis

; 76(6): 960-977.

Rheumaklinik, Ratingen, Germany. Rolf Rau, MD;

Gertraud Herborn, MD. Benefit and risk of methotrexate

treatment in rheumatoid arthritis, Clin Exp Rheumatol

; 22 (Suppl. 35): S83-S94.


  • There are currently no refbacks.

Comments on this article

View all comments

Copyright (c) 2018 Journal of Advanced Research in Ayurveda, Yoga, Unani, Sidhha & Homeopathy (ISSN: 2394-6547)